[The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)]

Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(12):21-4.
[Article in Russian]


Despite significant symptomatic effect of levodopa, in most patients the stable 24 hour's effect changed for alterations of movement symptoms (fluctuations, dyskinesia) after 2-3 years of the therapy. These complications may be reduced due to the constant (physiologic) stimulation of post-synaptic dopamine receptors that, to a certain degree, provides the drug stalevo, which contains levodopa and 2 enzyme inhibitors, dopa decarboxylase (carbidopa) and catechol-O-methyltransferase (entacapone). The results of the study demonstrated beneficial effects of stalevo as compared to traditional therapy in patients with "wearing off" and "on-off" phenomena.

Publication types

  • Comparative Study
  • English Abstract
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Activities of Daily Living
  • Aged
  • Ambulatory Care Facilities
  • Carbidopa / administration & dosage*
  • Catechols / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Humans
  • Levodopa / administration & dosage*
  • Male
  • Outpatients*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome


  • Catechols
  • Drug Combinations
  • Stalevo
  • Levodopa
  • Carbidopa